ClinicalTrials.gg
CompletedNCT01293747Updated Oct 13, 2011

Pharmacokinetics of Injectable Estradiol and Progesterone Microspheres Suspension

A Phase 1 interventional study of Estradiol + Progesterone and Estradiol + Progesterone in Menopause, sponsored by Productos Científicos S. A. de C. V.. Completed at 1 site in Mexico. Open to female participants aged 45 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-10-13.

Sponsored by Productos Científicos S. A. de C. V. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
45 Years to 65 Years
Sex
Female
01

Study summary

Phase I pharmacokinetic study

Main objective:

To determine plasmatic profiles and pharmacokinetic parameters of estradiol and progesterone on each of the formulations studied, after multiple-dose administration

Study design:

Randomized, controlled, open-label, parallel, pharmacokinetic study

Sites: 1

Subjects: 30 postmenopausal women

Read the detailed description

Sites: 1

Phase: 1

Main objective:

To determine plasmatic profiles and pharmacokinetic parameters of estradiol and progesterone on each of the formulations studied, after multiple-dose administration.

Secondary objectives:

To determine bioavailability of each of the formulations studied, after multiple-dose-administration. Describe tolerability of each of the formulations studied, after multiple-dose administration.

Study design: Randomized, controlled, open-label, parallel, pharmacokinetic study

Investigational Products:

  • Estradiol and progesterone microspheres aqueous suspension (1 mg/20 mg)
  • Estradiol and progesterone microspheres aqueous suspension (0.5 mg/15 mg)

Study subjects: 30 postmenopausal women 45 - 65 years old

Brief description: After written informed consent, 30 eligible women will be randomized to study treatments (one IM injection each 28 days, for a total of 4 doses). Blood samples will be obtained for pharmacokinetic study.

02

Conditions studied

  • Menopause

Keywords

  • Estrogen
  • Progesterone
  • Microspheres
  • Menopause
  • Pharmacokinetics
03

In context

Lead sponsor

Productos Científicos S. A. de C. V. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female
  • 45 to 65 years old
  • Able to read and write
  • equal or below 34.99 kg/m2
  • Healthy
  • Normal uterus
  • Time availability

Exclusion criteria

Exclusion Criteria:

  • to progesterone or related compounds
  • Hypersensitivity to estrogens
  • Hysterectomy
  • History or present hormone-dependent tumor
  • History or present uterine cervix dysplasia
  • Abnormal and clinically-significant laboratory test results
  • Family history of breast cancer
  • History of thromboembolic disease
  • Non-controlled hypertension
  • History of stroke
  • History of cardiac valve surgery
  • Renal failure
  • Hepatic failure
  • Non-controlled diabetes
  • History of serious neurologic disease
  • Reduced mobility
  • Anemia
  • Previous or concomitant hormone therapy
  • Previous or concomitant therapy with inhibitors or inductors of cytochrome
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Estradiol 0.5 mg/Progesterone 15 mg microspheres

    Estradiol 0.5 mg and progesterone 15 mg microspheres injectable aqueous suspension

    Drug: Estradiol + Progesterone

  • Experimental
    Estradiol 1 mg/Progesterone 20 mg microspheres

    Estradiol 1 mg and progesterone 20 mg microspheres injectable aqueous suspension

    Drug: Estradiol + Progesterone

Interventions

  • DrugEstradiol + Progesterone

    Drug pages: Estradiol · Progesterone

    Estradiol 1 mg and progesterone 20 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.

  • DrugEstradiol + Progesterone

    Drug pages: Estradiol · Progesterone

    Estradiol 0.5 mg and progesterone 15 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics

    Estrogen and progesterone plasma concentrations and pharmacokinetic parameters.

    Time frame: 0 - 60 Days

Secondary outcomes

  1. Number of Participants with Adverse Events as a Measure of Safety and Tolerability

    Number of Participants with Adverse Events as a Measure of Safety and Tolerability. Adverse events will be evaluated through periodic clinical evaluations and laboratory tests (comparison between enrollment and discharge).

    Time frame: 0 - 60 days

07

Study locations

1 site
  • Asociación Mexicana para la Investigación Clínica, A. C. (AMIC)
    Pachuca, Hidalgo 42090, Mexico
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2011, a primary completion of Aug 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 10, 2011
First posted
Feb 11, 2011
Start
Feb 2011
Primary completionActual
Aug 2011
CompletionActual
Oct 2011
Last update
Oct 13, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 13, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01293747
Lead sponsor
Productos Científicos S. A. de C. V.
Responsible party
Roberto Bernardo Escudero (Principal Investigator, Productos Científicos S. A. de C. V.) — Principal investigator
First posted
Feb 11, 2011
Start date
Feb 2011
Primary completion
Aug 2011
Completion
Oct 2011
Last update
Oct 13, 2011

Study contacts

Roberto Bernardo, MSc
principal investigator · Asociación Mexicana para la Investigación Clínica, A. C. (AMIC)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Estradiol · Progesterone

Other studies from this sponsor

Productos Científicos S. A. de C. V.

Start the discussion